Yifeng Pharmacy Chain Co., Ltd. (SHA:603939)
China · Delayed Price · Currency is CNY 22.22
-0.09 (-0.40%)
May 8, 2026, 3:00 PM CST
Yifeng Pharmacy Chain Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 23,809 | 23,733 | 23,295 | 22,078 | 19,382 | 14,807 |
Other Revenue | 700.33 | 700.33 | 767.13 | 510.66 | 504.62 | 519 |
| 24,509 | 24,433 | 24,062 | 22,588 | 19,886 | 15,326 | |
Revenue Growth (YoY) | 1.70% | 1.54% | 6.53% | 13.59% | 29.75% | 16.60% |
Cost of Revenue | 14,936 | 14,915 | 14,492 | 14,030 | 12,082 | 9,184 |
Gross Profit | 9,573 | 9,518 | 9,570 | 8,558 | 7,805 | 6,143 |
Selling, General & Admin | 7,027 | 7,041 | 7,262 | 6,450 | 5,782 | 4,717 |
Research & Development | 26.95 | 27.92 | 33.94 | 33.55 | 25.31 | 15.64 |
Other Operating Expenses | 60.98 | 57.05 | 52.63 | 57.59 | 59.1 | 28.18 |
Operating Expenses | 7,114 | 7,126 | 7,347 | 6,546 | 5,877 | 4,765 |
Operating Income | 2,459 | 2,392 | 2,224 | 2,012 | 1,928 | 1,377 |
Interest Expense | -149.8 | -166.75 | -221.37 | -160.53 | -165.21 | -168.99 |
Interest & Investment Income | 166.33 | 172.26 | 180.78 | 135.66 | 80.08 | 98.51 |
Other Non Operating Income (Expenses) | -17.23 | -22.83 | -25.18 | -18.94 | -12.81 | -10.03 |
EBT Excluding Unusual Items | 2,458 | 2,375 | 2,158 | 1,969 | 1,830 | 1,297 |
Impairment of Goodwill | -14.12 | -14.12 | -18.83 | - | - | - |
Gain (Loss) on Sale of Assets | 63.07 | 68.48 | 49.94 | 41.82 | 23.17 | 6.85 |
Asset Writedown | -4.61 | -3.02 | -3.84 | -12.73 | -10.33 | -1.43 |
Other Unusual Items | 29.58 | 29.94 | -2.66 | 39.87 | 34.99 | 35.49 |
Pretax Income | 2,532 | 2,456 | 2,182 | 2,038 | 1,877 | 1,338 |
Income Tax Expense | 648.64 | 625.37 | 529.67 | 456.66 | 454.06 | 347.16 |
Earnings From Continuing Operations | 1,884 | 1,831 | 1,653 | 1,581 | 1,423 | 990.75 |
Minority Interest in Earnings | -155.02 | -152.54 | -124.21 | -168.95 | -161.58 | -102.86 |
Net Income | 1,729 | 1,678 | 1,529 | 1,412 | 1,262 | 887.88 |
Net Income to Common | 1,729 | 1,678 | 1,529 | 1,412 | 1,262 | 887.88 |
Net Income Growth | 10.01% | 9.81% | 8.26% | 11.90% | 42.12% | 19.42% |
Shares Outstanding (Basic) | 1,217 | 1,216 | 1,213 | 1,207 | 1,202 | 1,193 |
Shares Outstanding (Diluted) | 1,234 | 1,234 | 1,233 | 1,207 | 1,211 | 1,203 |
Shares Change (YoY) | -0.20% | 0.12% | 2.15% | -0.37% | 0.70% | 4.01% |
EPS (Basic) | 1.42 | 1.38 | 1.26 | 1.17 | 1.05 | 0.74 |
EPS (Diluted) | 1.40 | 1.36 | 1.24 | 1.17 | 1.04 | 0.74 |
EPS Growth | 10.23% | 9.68% | 5.98% | 12.32% | 41.13% | 14.81% |
Free Cash Flow | 3,017 | 3,036 | 3,539 | 3,884 | 3,333 | 1,322 |
Free Cash Flow Per Share | 2.44 | 2.46 | 2.87 | 3.22 | 2.75 | 1.10 |
Dividend Per Share | 0.700 | 0.700 | 0.650 | 0.417 | 0.238 | 0.179 |
Dividend Growth | 7.69% | 7.69% | 55.99% | 75.01% | 33.31% | 29.98% |
Gross Margin | 39.06% | 38.96% | 39.77% | 37.89% | 39.25% | 40.08% |
Operating Margin | 10.03% | 9.79% | 9.24% | 8.91% | 9.69% | 8.99% |
Profit Margin | 7.05% | 6.87% | 6.35% | 6.25% | 6.35% | 5.79% |
Free Cash Flow Margin | 12.31% | 12.42% | 14.71% | 17.19% | 16.76% | 8.63% |
EBITDA | 2,718 | 2,654 | 2,495 | 2,231 | 2,115 | 1,521 |
EBITDA Margin | 11.09% | 10.86% | 10.37% | 9.88% | 10.63% | 9.93% |
D&A For EBITDA | 258.81 | 261.36 | 271.58 | 218.51 | 186.98 | 143.94 |
EBIT | 2,459 | 2,392 | 2,224 | 2,012 | 1,928 | 1,377 |
EBIT Margin | 10.03% | 9.79% | 9.24% | 8.91% | 9.69% | 8.99% |
Effective Tax Rate | 25.62% | 25.46% | 24.27% | 22.41% | 24.19% | 25.95% |
Revenue as Reported | 24,509 | 24,433 | 24,062 | 22,588 | 19,886 | 15,326 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.